Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data
Cancers · 08.01.2024 · 16 (2) · 267
DOI: 10.3390/cancers16020267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 08.01.2024. Verfasst von Ibon Gurruchaga Sotés und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The combination of gemcitabine and dacarbazine has exhibited efficacy in terms of progression-free survival (PFS) and overall survival (OS) for aSTSs, albeit without robust confirmation from larger clinical trials.
Methods
We conducted a retrospective study in a single institution involving aSTS patients treated with gemcitabine and dacarbazine.
Results
95 patients were assessed, pointing to a benefit in PFS of 3.5 months and an OS of 14.2 months. Patients with translocated histotypes had better PFS, while those with platelet–lymphocyte ratios (PLRs) surpassing a specific threshold or lower albumin levels had poorer overall survival.
Conclusions
This study validates previous findings from three phase I–II trials, affirming the utility of this treatment approach in routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain.
- Instituto de Investigación Sanitaria de Aragón, 50009 Zaragoza, Spain.
- Department of Pathology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
- Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
ORCID-Profile: Ibon Gurruchaga Sotés, M Carmen Gómez-Mateo, Javier Martínez-Trufero
Zitieren
APA
Gurruchaga Sotés, I., Gómez-Mateo, M. C., Ortega Izquierdo, M. E., & Martínez-Trufero, J. (2024). Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data. Cancers, 16(2), 267. https://doi.org/10.3390/cancers16020267
Vancouver
Gurruchaga Sotés I, Gómez-Mateo MC, Ortega Izquierdo ME, Martínez-Trufero J. Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data. Cancers. 2024;16(2):267. doi:10.3390/cancers16020267
BibTeX
@article{GurruchagaSots2024,
author = {Gurruchaga Sotés, Ibon and Gómez-Mateo, M Carmen and Ortega Izquierdo, María Eugenia and Martínez-Trufero, Javier},
title = {Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data},
journal = {Cancers},
year = {2024},
volume = {16},
number = {2},
pages = {267},
doi = {10.3390/cancers16020267}
}
EUVIMED